Digestive Diseases
| Ulcerative colitis
Digestive Diseases
Ulcerative colitis
COMMAND RCT: Efficacy and safety of risankizumab maintenance in moderate-to-severely active UC
book_2
Source:
ECCO 2024 - Oral session
calendar_today
Published on Medfyle:
March 2024
import_contacts
7
min
headphones
2
min
In this medfyle
The IL-23 pathway is important in UC pathogenesis. New data presented at ECCO 2024 explore maintenance therapy with risankizumab, comparing continued SC treatment to withdrawal in those who were responders at 12 weeks in the lead-in study.
Expert commentary
About this Medfyle
Read more
arrow_downward
Hide
arrow_upward
©2024 Medfyle. All rights reserved.
Source: Louis E, Panaccione R, Parkes G, et al. OP06 Risankizumab Maintenance Therapy in Patients With Moderately to Severely Active Ulcerative Colitis: Efficacy and Safety in the Randomised Phase 3 COMMAND Study. J Crohns Colitis 2024;18(suppl1):jjad212.0006 [OP06]
The information and data provided is for information purposes only.
The author(s) of the original article had no involvement in the creation of this content.
